CCL22 and neoplasm: These include increased tumor expression of CCR7 that indicates poor prognosis in mccRCC patients treated with TKIs [13] and increased CXCR4 [7], CXCL5 [8], CCL4 [9], CCL22 [10], and IL-1 [11], which have been linked to poor outcomes by promoting high proliferation rates/aggressive phenotypes.